Archive

Author Archive

RegMed Competitive and Market Intelligence, 1/25/12, stocks retreat, home sales down as expected, market way over too over-bought and earnings will be hit and miss

January 25th, 2012 No comments

   The 6 W’s: Who, what, where, when, why and what of it … Read more…

Advanced Cell Technology (OTC BB: ACTC) additional Stargardt’s Disease Patient undergoes hESC Transplantation

January 25th, 2012 No comments

                               

           At UCLA’s Jules Stein Eye Institute

Read more…

NeoStem’s (Amex: NBS) Amorcyte, enrolls 1st Patient in AMI PreSERVE P2 Trial

January 25th, 2012 No comments

  PreSERVE Phase 2 Trial for Acute Myocardial Infarction Read more…

Categories: NeoStem (AMEX: NBS)

RegMed Daily, Pre-Open, 1/25/12, futures in narrow range, mixed opening anticipated

January 25th, 2012 No comments

     Good morning! Here’s what you … might need to know to start the day. Read more…

Categories: RegMed Daily Pre-Open

RegMed Daily, Closing Bell, 1/24/12, stocks finish mixed, Dow down again, NASDAQ barely up

January 24th, 2012 No comments

       End of Day, Cause and Effect … Read more…

RegMed Competitive and Market Intelligence, 1/24/12, VIX up, stocks retreat shaving losses, EU issues drag on

January 24th, 2012 No comments

       The 6 W’s: Who, what, where, when, why and what of it … Read more…

ImmunoCellular Therapeutics (OTC BB: IMUC), P2 Clinical Trial for the Treatment of Glioblastoma

January 24th, 2012 No comments

     P2 Clinical Trial of ICT-107 for the Treatment of Glioblastoma

Read more…

BioTime (Amex:BTX) licenses Technology for key Regulatory Gene

January 24th, 2012 No comments

Regulatory Gene Underlying Cancer and Stem Cell Reprogramming from the Wistar Institute Read more…

Categories: BioTime (AMEX:BTX)

Acute Mycardial Infaraction (AMI) Update and Review

January 24th, 2012 No comments

A series of clinical trial results investigating stem and progenitor cells for the treatment of heart attacks has been reported of late …

Read more…

Cytori (CYTX), Adipose Stem Cell Heart Attack (AMI) Trial Data Published

January 24th, 2012 No comments

APOLLO Trial demonstrated Safety & Feasibility and Improvements in Cardiac Function Read more…